Loading...
sLAG-3 in non-small-cell lung cancer patients’ serum
BACKGROUND: Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed c...
Na minha lista:
| Udgivet i: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6097502/ https://ncbi.nlm.nih.gov/pubmed/30147330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S164178 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|